StockVS

NASDAQ · USD

BriaCell Therapeutics Corp. (BCTXZ) Stock Analysis

BriaCell Therapeutics Corp. (BCTXZ) is a stock listed on NASDAQ and quoted in US Dollar.

BCTXZ

$0.19

−$0.00 (−2.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCTXZ with… →

BCTXZ Key Statistics

As of Sep 4, 2026
Trading
Open
$0.18
Previous Close
$0.19
Day's Range
0.18–0.19
52-Week Range
0.18–0.19
Volume
5.62K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.52
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$4.79M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCTXZ Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−52.56%
2025 (partial year)+0.00%

As of September 4, 2026.

BCTXZ Revenue and Earnings by Fiscal Year

FY ends July
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$4.79M
2023$0.00−$20.30M
2022$0.00−$26.84M
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00−$33.33M−$4.79M
2023$0.00−$23.27M−$20.30M
2022$0.00−$15.29M−$26.84M

Annual figures as reported, in the company's reporting currency. As of July 31, 2024.

Analysis

Data-derived

Company Overview

BriaCell Therapeutics Corp. trades under the ticker BCTXZ.

The most recent close on file for BCTXZ is $0.19, dated September 4, 2026. That is $0.00 (−2.37%) against the previous close. Over the past 52 weeks the price has ranged from $0.18 to $0.19. The latest close sits 2.15% above that 52-week low.

Financial Health

In fiscal 2024, BriaCell Therapeutics Corp. reported revenue of $0.00. The same year closed with a net loss of $4.79M. Profit margin runs at 0%.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

The stored price history starts on December 18, 2025, and the total return since then is −52.56%. The reported beta is 1.52.

Growth & Income

No dividend is on file for BCTXZ.

2026 is still running; the price is −52.56% year to date.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Visit website →